Merus报告说,在治疗高级头部和颈部癌方面,Photosematamab的中期数据很有希望。 Merus reports promising interim data for petosemtamab in treating advanced head and neck cancer.

Merus宣布了临时临床数据,表明其药物Photosematamab在治疗以前接受过治疗的病人的复发/转移头部和颈部腐蚀性细胞癌方面显示出有希望的功效和安全性。 Merus announced interim clinical data showing that its drug, petosemtamab, demonstrates promising efficacy and safety in treating recurrent/metastatic head and neck squamous cell carcinoma in patients who have been previously treated. 与目前的治疗方法相比,该药物的回复率为36%,存活率良好。 The drug showed a 36% response rate and favorable survival rates compared to current treatments. 梅鲁斯计划进一步进行临床试验,包括与pembrocolizumab结合进行临床试验,预计在2025年进行更新。 Merus plans further clinical trials, including a combination with pembrolizumab, with updates expected in 2025.